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A small population of CD55-CD59- blood cells was detected in a patient 
who developed donor-type late graft failure after allogeneic stem cell 
transplantation (SCT) for treatment of aplastic anemia (AA). Chimerism 
and PIG-A gene analyses showed the paroxysmal nocturnal 
hemoglobinuria (PNH)-type granulocytes to be of a donor-derived stem 
cell with a thymine insertion in PIG-A exon 2. A sensitive mutation-specific 
PCR-based analysis detected the mutation exclusively in DNA derived 
from the donor bone marrow (BM) cells. The patient responded to 
immunosuppressive therapy and achieved transfusion independence. The 
small population of PNH-type cells was undetectable in any of the 50 SCT 
recipients showing stable engraftment. The de novo development of 
donor-cell derived AA with a small population of PNH-type cells in this 
patient supports the concept that glycosyl phosphatidylinositol anchored 
protein deficient stem cells have a survival advantage in the setting of 
immune mediated BM injury.  
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Introduction 
Although small populations of CD55-CD59- blood cells are often detectable 
in patients with aplastic anemia (AA), it remains unclear how such 
paroxysmal nocturnal hemoglobinuria (PNH)-type cells arise. 1 We recently 
encountered a patient with immune-mediated late graft failure (LGF) 
following allogeneic stem cell transplantation (SCT) for treatment of AA. 
Analyses of the the patient’s peripheral blood (PB) and bone marrow (BM) 
showed an HSC of donor origin with mutant PIG-A, supporting the concept 
that glycosyl phosphatidylinositol anchored protein (GPI-AP) deficient 
stem cells have a survival advantage in the setting of immune mediated BM 
injury. 
 
Materials and methods 
Patients 
A 59-year-old male underwent allogeneic PBSCT from an HLA-matched 
sibling donor after conditioning with fludarabin 120 mg/m2, 
cyclophosphamide 1200 mg/m2, and antithymocyte globulin 60 mg/kg for 
treatment of very severe AA in April 2002 (Table 1) and achieved complete 
donor chimerism with normal blood cell counts. In January 2006, he 
developed pancytopenia and was diagnosed as having LGF without 
residual recipient cells. The patient underwent a second PBSCT from the 
original donor without preconditioning on February 8, 2006. Pancytopenia 
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resolved completely by day 16 post PBSCT. However, at approximately 
day 60, the blood counts decreased gradually, and the patient became 
transfusion dependent. On day 196 after the second PBSCT, the WBC was 
5.3x109 /L with 17% neutrophils, the Hb concentration was 75 g/L, and the 
platelet count was 22x109 /L. Treatment with horse antithymocyte globulin 
(ATG) and cyclosporine was started on day 205 after the second PBSCT. 
Transfusions were terminated after 88 days of the immunosuppressive 
therapy. Although he presently receives low-dose tacrolimus for treatment 
of chronic graft-versus host disease which developed 1 year after the 
second PBSCT, his pancytopenia has markedly improved as shown in Table 
1. PB and BM of the patient were subjected to analyses of chimerism, flow 
cytometry to detect CD55-CD59- cells, and PIG-A gene analysis. 
As controls, the PB from 51 SCT recipients (48 with hematologic 
malignancies and 3 with AA) who achieved a complete recovery of 
donor-derived hematopoiesis were subjected to flow cytometric analysis for 
the screening of CD55-CD59- cells. Of the 51 patients, 4 and 23, 
respectively had acute graft-versus-host disease (GVHD) ≥grade II and 
chronic GVGD at sampling.  
BM aspirates were obtained from the patient’s donor and 10 healthy 
individuals for PIG-A gene analysis. All patients and healthy individuals 
gave their informed consent according to the Declaration of Helsinki for 
blood examination, and the experimental protocol for PIG-A gene analysis 
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was approved by our participating institutional ethics committee (No.157).   
Detection of PNH-type cells 
To detect GPI-AP deficient (GPI-AP-), PNH-type cells, we performed 
high-sensitivity 2-color flow cytometry of granulocytes and red blood cells 
(RBCs), as described previously. 1 The presence of ≥0.003% 
CD55-CD59-CD11b+ granulocytes and ≥0.005% 
CD55-CD59-glycophorin-A+ RBCs was defined as an abnormal increase 
based on the results in 183 healthy individuals. 2  
Cell sorting and chimerism analysis  
CD3+cells were isolated from the PB mononuclear cells of the patient using 
MACS CD3 Microbeads (Miltenyi Biotec, Auburn, CA). The 
CD55-CD59-CD11b+ granulocytes were separated from the 
CD55+CD59+CD11b+ granulocytes with a cell sorter (JSAN; Bay 
Bioscience Co., Ltd., Yokohama, Japan). More than 95% of the sorted cells 
were CD55-CD59-CD11b+. The D1S80 locus was amplified from DNA of 
different cell populations with an AmpliFLP D1S80 PCR Amplification Kit 
(Perkin-Elmer Cetus, Norwalk, CT).  
PIG-A gene analysis 
The coding regions of PIG-A were amplified by semi-nested PCR or nested 
PCR from DNA extracted from the sorted PNH-type cells using 12 primer 
sets 3,4 (Supplemental table online), and 6 ligation reactions were used to 
transform competent Escherichia coli JM109 cells (Nippon Gene, Tokyo, 
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Japan).  Five clones were selected randomly from each group of 
transfectants and subjected to sequencing with a BigDye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and an ABI 
PRISM 3100 Genetic Analyzer (Applied Biosystems).  
Amplification refractory mutation system (ARMS)-PCR 
On the basis of a mutant sequence detected in PIG-A of the patient, a 
nested amplification refractory mutation system (ARMS) forward primer 
with a 3’-terminal nucleotide sequence complementary to the mutant 
sequence was prepared 5 (Supplemental table online). To enhance the 
specificity, a mismatch at the penultimate nucleotide position of the 
mutation site was incorporated in the ARMS forward primer (P1).6,7 P1 and 
a reverse primer (P3) were used to amplify a 127 bp fragment containing 
the mutant sequence from the exon 2 amplified product. PCR was 
conducted under the following conditions; denaturation for 30 seconds at 
94 °C, annealing for 60 seconds at 64 °C and extension for 90 seconds at 
72 °C for 20 cycles. Another forward primer (P2), complementary to the 
wild-type PIG-A sequence upstream of the mutation site, was used in 
combination with P3 to amplify an internal control according to the same 
condition of ARMS-PCR.  
 
Results and discussion 
PNH-type cells were not detected in the donor or the patient at the time 
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of development of the first LGF, whereas 0.147% PNH-type granulocytes 
and 0.019% PNH-type RBCs were detected in the PB obtained at the time 
of development of the second LGF (Figure 1A). Similar percentages of 
PNH-type blood cells were detectable in the PB of the patient 6 and 14 
months later. When PB from 51 SCT recipients was examined, none of the 
patients were found to have detectable PNH-type cells (data not shown). 
PNH-type blood cells were also undetectable in a donor PB sample 
obtained 21 months later. 
The D1S80 locus allelic pattern of the PNH-type granulocytes in the 
patient was compatible to that of the donor (Figure 1B). The emergence of 
donor-derived PNH-type cells and hematologic improvement after 
immunosuppressive therapy suggest that LGF arises as a result of de novo 
development of AA which affects the donor-derived hematopoietic stem 
cells (HSCs).  
PIG-A gene analysis of the DNA prepared from the sorted PNH-type 
cells of the patient obtained at the development of LGF and 6 months later 
showed an insertion of thymine at position 593 (codon 198) in 3 of 5 clones 
and 5 of 5 clones examined, respectively (Figure 1C). Mutations in other 
exons were not identified. The presence of a single PIG-A mutation in 
PNH-type granulocytes and its persistence over 6 months suggests that 
these PNH-type cells are derived from a mutant HSC rather than from a 
committed granulocyte progenitor cell. Moreover, an ARMS-PCR with a 5’ 
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primer specific to the mutated sequence amplified a 127 bp fragment from 
DNA of the donor BM as well as of the recipient BM and PB while it failed 
to amplify the same fragment in donor PB and in BM of all 10 healthy 
individuals (Figure 1D).  
These experiments demonstrate that the PIG-A mutant HSC was present 
in the BM of the donor in a dormant state and was transplanted into the 
recipient and provide, for the first time, in vivo evidence that PIG-A mutant, 
GPI-AP deficient HSCs have a survival advantage in the setting of immune 
mediated BM injury. Similarly, relative resistance to immune injury likely 
accounts for the high incidence of PNH observed in association with 
acquired AA.  
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Figure1. Analysis of PNH-type cells after the second PBSCT. (A) 
High-sensitivity flow cytometry detected small populations of 
CD55-CD59-cells in both granulocytes and red blood cells at the 
development of the second LGF as well as in those obtained 6 and 12 
months later, but did not detect PNH-type cells in the donor or in the 
recipient before the second PBSCT. The numbers denote the proportion of 
PNH-type cells in CD11b+ granulocytes or glycophorin A+ RBCs. (B) 
D1S80 allelic patterns of sorted GPI-AP- granulocytes, GPI-AP+ 
granulocytes, and CD3+ lymphocytes. The polymerase chain reaction 
(PCR) products were subjected to 8% polyacrylamide gel electrophoresis 
and visualized by silver staining. (C) Nucleotide sequences of PIG-A exon 
2 in DNA from PNH-type granulocytes obtained 6 and 12 months after the 
second PBSCT. (D) A schematic illustration for ARMS-PCR is shown. 
Primer positions for the first, second are shown by short arrows. A black 
box and adjacent lines represent exon 2 and introns, respectively. (E) 
Amplified products of control PCR (the upper gel) and ARMS-PCR (the 
lower gel) were electrophoresed in 12.5% polyacrylamide gel and 
visualized by the silver staining. A pMD20-T vector containing the mutated 
exon 2 fragment was used as a positive control for ARMS-PCR. The 
template DNA derives from a plasmid containing the mutated exon 2 in 
lane 1, donor BM in lane 2, donor PB in lane 3, recipient BM in lane 4, 
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recipient PB in lane 5, and BM from healthy individuals in lanes 6-11. PCR 
with a 5’primer specific to the nucleotide sequence upstream of the mutated 
sequence amplified a 261 bp fragment from DNA of the donor and all 
healthy individuals. 
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Donor Before 1st 
SCT 
Before 2nd 
SCT at ATG therapy
20 months of 
ATG therapy 
 Apr 2002 May 2007 Apr 2002 Jan 2006 Aug 2006 Apr 2008 
White Blood Cell Count, x109/L 7.0 5.1 1.2 1.7 5.3 4.0 
Neutrophil Proportions (%) 77 65 0 0 17 62 
Red Blood Cell Count, x1012/L 4.21 4.43 2.20 2.75 2.07 3.04 
Reticulocytes, x109/L not tested 35 2 3 26 61 
Hemoglobin, g/L 146 150 72 89 75 120 
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Supplemental table  PCR primers 
Primer Sequence 5' → 3' Location
Annealing 
Temperature, °C Product size, bp 
1st PCR primers    
2-1F* GAGCTGAGATCCTGTTTTAC intron1 58.0 625 
2-1R* GTATCACAAAGAGACACGG exon2 58.0 - 
2-2F* CATTGCTCAGGTACATATTTGTT exon2 58.0 421 
2-2R* AAAGTCTACAATGCAATTATAGC intron2 58.0 - 
3F* AAGTGGATTCTCAGTCGTTCTGGT intron2 58.0 247 
3R* CTTCTCCCTCAAGACAACATGAA intron3 58.0 - 
4F ACTCCTTTCTTCCCCTCTCATT intron3 58.0 206 
4R CACAGAAATCCCAACCATGAAT intron4 58.0 - 
5F† TCTTCCTGAGGTATGATTATGGTG intron4 58.0 306 
5R CATCAAGTAAGAGTTCAGACACAAT intron5 58.0 - 
6F† GTCATTGTTTATCATGGGACAG intron5 58.0 360 
6R† TCTTACAATCTAGGCTTCCTTC exon6 58.0 - 
     
2nd (nested or semi-nested) PCR primers    
2-1F* GAGCTGAGATCCTGTTTTAC intron1 60.0 598 
2-1R2 TTGTTTGTAAGCACCGAG exon2 60.0 - 
2-2F2 GAGAGAGTCACGATAATCCA exon2 60.0 395 
2-2R* AAAGTCTACAATGCAATTATAGC intron2 60.0 - 
3F2 ATTAATATCTCCAACATTCAACTTT intron2 60.0 203 
3R* CTTCTCCCTCAAGACAACATGAA intron3 60.0 - 
4F ACTCCTTTCTTCCCCTCTCATT intron3 60.0 193 
4R2 ACCATGAATGCCCTCAAAGC intron4 60.0 - 
5F2 GATTATGGTGGAGTATGTGTTC intron4 60.0 269 
5R2 ATCTTTTCTCAGCATGTGAC intron5 60.0 - 
6F2 TGATGGGTGAAAGTGCTC intron5 60.0 329 
6R† TCTTACAATCTAGGCTTCCTTC exon6 60.0 - 
     
ARMS-PCR Primers    
P1 ACTGTACTAAGAGCAGCAGTT exon2 64.0 127 
P2 TTCAGACAGTCTTCACGG exon2 64.0 261 
P3 GTCTGCTGACAACAACAATAG exon2 64.0 - 
* primers derived from a reference by Kai et al.3 
† primers derived from a reference by Mortazavi et al.4 
 
 
